Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. (Q45995789)
Jump to navigation
Jump to search
scientific article published on 26 May 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. |
scientific article published on 26 May 2009 |
Statements
1 reference
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. (English)
1 reference
Gilles Montalescot
1 reference
Lars Wallentin
1 reference
Robert A Harrington
1 reference
Freek Verheugt
1 reference
Deepak L Bhatt
1 reference
Witold Ruzyllo
1 reference
John H Alexander
1 reference
Richard C Becker
1 reference
Shaun G Goodman
1 reference
Keith A A Fox
1 reference
Steen Husted
1 reference
Jose Lopez-Sendon
1 reference
Mikhail Ruda
1 reference
Puneet Mohan
1 reference
Frank Cools
1 reference
Mikael Dellborg
1 reference
APPRAISE Steering Committee and Investigators
1 reference
Filippo Crea
1 reference
Kurt Huber
1 reference
Basil S Lewis
1 reference
26 May 2009
1 reference
1 reference
119
1 reference
22
1 reference
2877-2885
1 reference